文献速递细菌感染、耐药与抗菌药物

耐药指导的淋病治疗:一项前瞻性临床研究

Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究采用基因型PCR检测淋病奈瑟菌gyrA丝氨酸91密码子状态,在多中心前瞻性临床研究中评估单剂口服环丙沙星500mg治疗培养阳性淋病的疗效。106例野生型gyrA丝氨酸基因型感染者中,符合方案人群的微生物学治愈率为100%(95%单侧CI 97.5-100%)。结论认为耐药指导的单剂口服环丙沙星治疗高效,广泛开展gyrA丝氨酸91基因分型在环丙沙星敏感为主的地区具有医学和公共卫生益处。

要点

  • gyrA丝氨酸91基因分型可预测淋球菌对环丙沙星的体外敏感性。
  • 野生型gyrA丝氨酸基因型淋病患者单剂口服环丙沙星500mg治愈率达100%。
  • 在环丙沙星敏感为主的地区推广该基因分型可带来医学与公共卫生益处。

核心结论

  • 耐药指导的淋病奈瑟菌感染单剂口服环丙沙星治疗高度有效。
  • 在多数淋球菌感染对环丙沙星敏感的地区,广泛引入并扩大gyrA丝氨酸91基因分型可带来显著医学和公共卫生益处。

研究设计与样本

  • 多中心前瞻性临床研究,采用基因型聚合酶链反应检测淋病奈瑟菌gyrA亚基A丝氨酸91密码子状态。
  • 纳入培养阳性淋病患者,给予单剂口服环丙沙星500mg,治疗后5-10天采集培养标本判定微生物学治愈。
  • 共106例受试者为培养阳性且gyrA丝氨酸为野生型基因型的淋病奈瑟菌感染。

主要发现

  • 符合方案人群中,单剂口服环丙沙星治疗的疗效为100%(95%单侧置信区间97.5-100%)。

临床怎么用

  • 对淋病患者可考虑先行gyrA丝氨酸91基因分型,野生型者选用单剂口服环丙沙星500mg治疗。
  • 在环丙沙星敏感占多数的地区推广该基因分型策略以指导淋病治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel treatment strategies to slow the continued emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae are urgently needed. A molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections. METHODS: Using a genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon, we conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure 5-10 days post-treatment. RESULTS: Of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% (95% 1-sided confidence interval, 97.5-100%). CONCLUSIONS: Resistance-guided treatment of N. gonorrhoeae infections with single-dose oral ciprofloxacin was highly efficacious. The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible. CLINICAL TRIALS REGISTRATION: NCT02961751.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Klausner JD, Bristow CC, Soge OO, et al. Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study. Clin Infect Dis. 2021. PMID: 32766725. doi:10.1093/cid/ciaa596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。